GATC Health Publishes a Multi-Omics Exosome Study Defining a New Therapeutic Path in Diabetes
Irvine, CA — May 11, 2026 — GATC Health is announcing the publication of “The Multi-Omics Profiling of Early-Passage Mesenchymal Stem Cell Exosomes Reveals Potential Targets for Attenuating Diabetic Inflammatory Pathophysiology,” now published in the American Journal of Biomedical Science & Research. The paper presents a multi-omics analysis of mesenchymal stem cell-derived exosomes and identifies a biologically differentiated, early-passage exosome profile with potential relevance for diabetes therapy. Authors include GATC’s Samuel Kho, Lukeman Kharrat, Waldemar Lernhardt, Eric J Mathur, Jayson Uffens, Ian Jenkins, and…
GATC Health Publishes a Digital Twin Framework for Therapeutic Development
New paper formalizes the multi-scale architecture behind Operon™ and advances GATC’s position in AI-native drug development Irvine, CA — May 08, 2026 — GATC Health has announced the publication of “A Multi-Scale, Evidence-Orchestrated Digital Twin Architecture for Therapeutic Development: A Systems-Theoretic Framework,” now published in Advances in Clinical and Medical Research. Authors include GATC’s Ian Jenkins, Vaishnavi Narayan, Waldemar Lernhardt, Valentina Savich, Eric Mathur, Robert Tinder, Jayson Uffens, and corresponding author Jonathan RT Lakey, plus Krista Casazza. The publication sets…
Drug Discovery News Covers GATC’s PNAS Breakthrough, Extending Media Momentum Around GATC-1021
Recent coverage in Drug Discovery News reinforces continued external interest in GATC’s AI-enabled discovery platform and the therapeutic promise of its non-opioid OUD candidate Irvine, CA — May 5, 2026 — GATC Health is pleased to share additional media momentum stemming from the company’s recent PNAS publication on GATC-1021, its AI-derived non-opioid drug candidate for opioid use disorder. In a recent feature, Drug Discovery News, a premier industry authority bridging academic breakthroughs and commercial drug development highlighted the program in an article…
GATC Health Senior Leadership Presents at Two Key Industry Forums Focused on AI, Capital Efficiency, and Addiction Innovation
GATC Health Senior Leadership Presents at Two Key Industry Forums Focused on AI, Capital Efficiency, and Addiction Innovation Recent participation at Biocom Converge and NDASA reinforced GATC’s differentiated position at the intersection of predictive AI, biotech finance, and human-impact therapeutic development Irvine, CA — April 30, 2026 — GATC Health is pleased to share recent visibility across two distinct but strategically aligned industry gatherings in late April: Biocom’s Converge Summit in South San Francisco and the NDASA 2026 Conference and Trade…
GATC Health Focuses on Identifying Distinct ALS Subtypes With Answer ALS and the LADDIA Initiative
GATC Health Focuses on Identifying Distinct ALS Subtypes With Answer ALS and the LADDIA Initiative Irvine, CA — April 28, 2026 — We are incredibly proud to be part of the next frontier in ALS research. As our partners at Answer ALS recently highlighted, the fight against ALS is officially moving beyond resource collection and into the era of computational discovery. In 2025, Answer ALS launched the LADDIA initiative—a groundbreaking collaboration between GATC Health, Pennington Biomedical Research Center, and Tulane University. Together,…
GATC Health Scientists and Leadership Featured as Authors on Two New Peer-Reviewed Publications Advancing AI-Driven Drug Discovery and Systems Biology
GATC Health Scientists and Leadership Featured as Authors on Two New Peer-Reviewed Publications Advancing AI-Driven Drug Discovery and Systems Biology New papers in American Journal of Biomedical Science & Research and Advances in Clinical and Medical Research reinforce the scientific framework behind GATC Health’s Operon™ platform and the broader shift toward biologically grounded AI in therapeutic development Irvine, CA — April 27, 2026 — GATC Health is pleased to share the publication of two new papers featuring GATC Health’s technology and…
GATC Health Receives Concentrated Media Visibility Across AI, Capital Markets and Regulatory Policy Conversations
Recent coverage in BioSpace and GEN highlights GATC’s growing relevance in industry discussions spanning AI adoption, biotech financing, development efficiency and FDA policy Irvine, CA — April 7, 2026 — GATC Health received a strong run of media attention over the past two weeks, with six notable inclusions across BioSpace and Genetic Engineering & Biotechnology News (GEN) that reinforced the company’s positioning at the intersection of AI-driven drug development, capital efficiency and regulatory strategy. The coverage featured commentary from Tyrone Lam, Dr. Rahul Gupta and Jayson Uffens, and placed GATC within some of the biopharma industry’s most…
GATC Health and UC Irvine Announce Landmark PNAS Publication Validating AI-Platform for Opioid Use Disorder Treatment
IRVINE, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- GATC Health Corp, a leading tech-bio company leveraging artificial intelligence (AI) to transform drug discovery and development, and researchers from the University of California, Irvine (UCI) today announced the publication of a joint study in the Proceedings of the National Academy of Sciences (PNAS). The peer-reviewed paper validates a novel drug candidate, GATC-1021, which was identified using GATC Health’s Operon™ AI platform to more precisely target the specific neurological dysregulations found in individuals with…
Fierce Biotech: AI model designs new treatment candidate for opioid addiction that cuts cravings in rats
Fierce Biotech: AI model designs new treatment candidate for opioid addiction that cuts cravings in rats By Darren Incorvaia Apr 6, 2026 3:00pm While the opioid epidemic is one of the most urgent public health emergencies facing the U.S., new therapeutic approaches for treating the underlying substance use disorder have lagged far behind. Scientists have now used an artificial intelligence program to design a compound that reduced fentanyl use in addicted rats, which could one day serve as a new tool to help patients…
A Historical Journey through Pharmacology, Total Synthesis, and Evolution Towards Iboga Alkaloid Analogs
AbstractIbogaine, a powerful psychedelic, has been used throughout the world for much of human history. Its diverse usage has led to a unique outlook of the indole alkaloid as both an integral part of life and a concerning psychedelic. The pharmacologic community showed initial interest in utilizing ibogaine for the treatment of a number of substance use disorders; however, difficulty in synthesis has largely hindered therapeutic development. This work aims to examine the history of ibogaine, including its pharmacological properties…
